Browsing by author "Anbalagan, Selvakumar"
Now showing items 1-5 of 5
-
An ionising radiation-induced specific transcriptional signature of inflammation-associated genes in whole blood from radiotherapy patients: a pilot study.
Cruz-Garcia, L; Badie, C; Anbalagan, S; Moquet, J; Gothard, L; et al. (BMC, 2021-05-03)BACKGROUND: This communication reports the identification of a new panel of transcriptional changes in inflammation-associated genes observed in response to ionising radiation received by radiotherapy patients. METHODS: ... -
Intratumoral Hydrogen Peroxide With Radiation Therapy in Locally Advanced Breast Cancer: Results From a Phase 1 Clinical Trial.
Nimalasena, S; Gothard, L; Anbalagan, S; Allen, S; Sinnett, V; et al. (ELSEVIER SCIENCE INC, 2020-11-15)PURPOSE: Hydrogen peroxide (H2O2) plays a vital role in normal cellular processes but at supraphysiological concentrations causes oxidative stress and cytotoxicity, a property that is potentially exploitable for the treatment ... -
Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study.
Andreyev, HJN; Matthews, J; Adams, C; Gothard, L; Lucy, C; et al. (ELSEVIER IRELAND LTD, 2022-03-01)BACKGROUND: Preclinical data suggest that combined gamma-tocotrienol with pentoxifylline ameliorates radiotherapy-induced gastrointestinal damage. AIM: To test whether gastrointestinal symptoms arising after radiotherapy, ... -
The applicability of scoring calyculin A-induced premature chromosome condensation (PCC) objects for dose assessment including for radiotherapy patients.
Sun, M; Moquet, J; Lloyd, D; Barnard, S; Anbalagan, S; et al. (S. Karger AG, 2023-10-19)As an extension to a previous study, a linear calibration curve covering doses from 0 to 10 Gy was constructed and evaluated in the present study using calyculin A-induced premature chromosome condensation (PCC) by scoring ... -
TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells.
Anbalagan, S; Ström, C; Downs, JA; Jeggo, PA; McBay, D; et al. (NATURE PORTFOLIO, 2021-03-29)Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient ...